Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 5/20 | 0.53 |
| ▸ | JAK2 | O60674 | 2/20 | 0.52 |
| ▸ | JAK3 | P52333 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 3/20 | 0.52 |
| ▸ | DRD4 | P21917 | 3/20 | 0.52 |
| ▸ | DRD3 | P35462 | 2/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | SCN8A | Q9UQD0 | 4/20 | 0.47 |
| ▸ | SCN1A | P35498 | 3/20 | 0.47 |
| ▸ | CCR2 | P41597 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153280 | 0.92 | OPRK1 (0.55) | DRD4ROCK2OPRK1SCN8ASCN1A | |
| SCHEMBL6153502 | 0.87 | OPRK1 (0.59) | DRD4OPRK1SCN8ASCN1AKCNH2 | |
| SCHEMBL6153437 | 0.84 | ROCK2 (0.60) | KAT2BJAK2JAK3DRD2DRD4 | |
| SCHEMBL6819786 | 0.79 | SCN8A (0.56) | DRD2DRD4ROCK2OPRK1SCN8A | |
| SCHEMBL6156841 | 0.77 | GAA (0.59) | DRD2DRD4ROCK2CCR2KCNH2 | |
| SCHEMBL6157012 | 0.76 | OPRK1 (0.56) | DRD4OPRK1KCNH2 | |
| SCHEMBL27936853 | 0.76 | DRD2 (0.57) | JAK2JAK3DRD2DRD4DRD3 | |
| SCHEMBL6153565 | 0.76 | SIGMAR1 (0.59) | DRD2DRD4DRD3OPRK1KCNH2 | |
| SCHEMBL6156960 | 0.75 | OPRK1 (0.55) | DRD4OPRK1KCNH2 | |
| SCHEMBL6153245 | 0.75 | GAA (0.65) | DRD4OPRK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | KAT2B 1194/4885JAK2 820/4885JAK3 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.